Agios Pharmaceuticals
Agios Pharmaceuticals' revenue rose 48.0% to $54 million in fiscal 2025. Its operating margin was −873.9%, up from −1,166.5% a year earlier. Free cash flow was −$377 million. The diluted share count rose 0.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Agios Pharmaceuticals does
Agios is a drug company focused on rare diseases, starting with blood disorders. Its main medicine, mitapivat, activates an enzyme called pyruvate kinase in red blood cells to treat hemolytic anemias, in which red blood cells break down too fast.
The drug is sold under the brand name PYRUKYND in the United States for anemia in adults with pyruvate kinase deficiency, and in the European Union and Great Britain for that condition. In the United States it is also approved, under the name AQVESME, for anemia in adults with thalassemia, an inherited blood disorder, and it has approval for thalassemia in Saudi Arabia. Agios earns revenue from selling these medicines.
The company is also testing mitapivat in sickle cell disease and in children with pyruvate kinase deficiency, and says it plans to seek US approval for sickle cell disease after meeting with the FDA. It describes a growing pipeline of other rare disease medicines.
Its biggest risks, as it describes them
- Its medicines may not sell well enough if it does not successfully commercialize them.
- Doctors and patients may not accept them, or it may not keep up the sales and marketing it needs.
- Clinical trials may be slow to enroll patients, and early results may not predict later ones.
- Trials held outside the United States may not be accepted by the FDA.
- It may spend limited resources on the wrong drug candidate or condition.
Income statement
From fiscal 2021 to 2024, earnings per share fell 24.0% a year and net income 25.1% a year, while the share count fell by 4%. Agios Pharmaceuticals then lost money in fiscal 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,286 | 1,100 | 806 | 1,500 | 1,200 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 17.8x | 13.3x | 12.3x | 11.9x | 11.5x |
| Quick ratio | 17.8x | 13.2x | 12.0x | 11.6x | 11.1x |
Cash flow
Projections
Project Agios Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Agios Pharmaceuticals shares on the open market, and 7 insiders sold $4.3 million, $4.1 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Sarah GheuensChief Medical Officer | Sold plan | 30,000 | $30.48 | $914,400 | Form 4 |
| Jul 1, 2026 | Sarah GheuensChief Medical Officer | Sold plan | 4,007 | $37.56 | $150,503 | Form 4 |
| Apr 2, 2026 | Brian GoffChief Executive Officer, Director | Sold plan | 19,068 | $34.71 | $661,850 | Form 4 |
| Apr 2, 2026 | James William BurnsChief Legal Officer | Sold plan | 3,280 | $34.71 | $113,849 | Form 4 |
| Apr 2, 2026 | Tsveta MilanovaChief Commercial Officer | Sold plan | 3,262 | $34.71 | $113,224 | Form 4 |
| Apr 2, 2026 | Cecilia JonesChief Financial Officer | Sold plan | 3,141 | $34.71 | $109,024 | Form 4 |
| Apr 2, 2026 | Krishnan ViswanadhanChief Corp Dev & Strategy | Sold plan | 2,959 | $34.71 | $102,707 | Form 4 |
| Apr 2, 2026 | Sarah GheuensChief Medical Officer | Sold plan | 2,940 | $34.71 | $102,047 | Form 4 |
| Mar 5, 2026 | Krishnan ViswanadhanChief Corp Dev & Strategy | Sold plan | 2,959 | $27.80 | $82,260 | Form 4 |
| Mar 3, 2026 | Theodore James Washburn Jr.Principal Accounting Officer | Sold | 5,272 | $28.88 | $152,255 | Form 4 |
| Mar 2, 2026 | Brian GoffChief Executive Officer, Director | Sold plan | 18,055 | $28.96 | $522,873 | Form 4 |
| Mar 2, 2026 | James William BurnsChief Legal Officer | Sold plan | 5,218 | $28.96 | $151,113 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −1,019.1% | −1,036.7% | −650.3% |
| Altman Z'' | 6.45 | 14.71 | 12.52 |
| Accruals ratio | −5.2% | 81.8% | −2.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
Compare
Put Agios Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | |
| Nektar Therapeutics | FY25 | −43.9% | −253.7% | −377.8% | — | — | 2 | Compare |
| Ocular Therapeutix | FY25 | −18.5% | −519.8% | −417.5% | — | — | 4 | Compare |
| Tango Therapeutics | FY25 | 48.3% | −178.4% | −224.3% | — | — | — | Compare |
| Nuvation Bio | FY25 | 699.0% | −338.7% | −288.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 70 | 43 | 94 | 118 | 0 | 0 | 14 | 27 | 36 | 54 |
| Revenue growth | 18.2% | −38.5% | 119.5% | 24.9% | −100.0% | — | — | 88.4% | 36.1% | 48.0% |
| Gross profit | 70 | 43 | 93 | 117 | 0 | 0 | 12 | 24 | 32 | 48 |
| Research and development | 220 | 293 | 341 | 214 | 221 | 257 | 280 | 296 | 301 | 340 |
| Operating income | −201 | −321 | −362 | −316 | −336 | −378 | −389 | −392 | −426 | −472 |
| Net income | −198 | −315 | −346 | −412 | −327 | 1,605 | −232 | −352 | 674 | −413 |
| Diluted EPS (US$) | −5.07 | −6.75 | −6.03 | −6.86 | −4.74 | 26.55 | −4.23 | −6.33 | 11.64 | −7.12 |
| Diluted shares (millions) | 39 | 47 | 57 | 60 | 69 | 60 | 55 | 56 | 58 | 58 |
| Cash flow | ||||||||||
| Cash from operations | 39 | −285 | −304 | −371 | −291 | −407 | −310 | −296 | −390 | −373 |
| Capital expenditure | 10 | 5 | 7 | 12 | 14 | 6 | 5 | 1 | 2 | 4 |
| Free cash flow | 29 | −290 | −311 | −383 | −305 | −413 | −314 | −297 | −392 | −377 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 802 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 42 | 48 | 73 | 58 | 62 | 54 | 49 | 45 | 43 | 53 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 574 | 568 | 805 | 718 | 670 | 1,286 | 1,100 | 806 | 1,500 | 1,200 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 619 | 614 | 858 | 891 | 853 | 1,438 | 1,239 | 937 | 1,663 | 1,297 |
| Total liabilities | 260 | 239 | 171 | 250 | 454 | 146 | 138 | 126 | 122 | 104 |
| Shareholders' equity | 359 | 376 | 688 | 640 | 400 | 1,292 | 1,101 | 811 | 1,541 | 1,193 |
| Margins and ratios | ||||||||||
| Gross margin | 100.0% | 100.0% | 98.5% | 98.9% | — | — | 88.0% | 89.3% | 88.6% | 88.3% |
| Operating margin | −287.6% | −745.8% | −384.0% | −268.2% | — | — | −2,732.1% | −1,459.5% | −1,166.5% | −873.9% |
| Net margin | −284.0% | −731.6% | −366.6% | −349.0% | — | — | −1,627.8% | −1,312.6% | 1,845.9% | −764.0% |
| Free cash flow margin | 41.0% | −673.9% | −329.9% | −324.5% | — | — | −2,207.6% | −1,107.5% | −1,072.7% | −698.3% |
| Rule of 40 (growth + FCF margin) | 59.2% | −712.4% | −210.5% | −299.6% | — | — | — | −1,019.1% | −1,036.7% | −650.3% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −56.4% | −85.7% | −65.1% | −62.0% | −63.0% | 189.7% | −19.4% | −36.8% | 57.3% | −30.2% |
| Return on assets | −38.2% | −51.0% | −47.0% | −47.0% | −37.5% | 140.1% | −17.3% | −32.4% | 51.8% | −27.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |